# DOC-17: PFC Clearance, RES Metabolism & Future Synthesis
## Document 17 of 17 — Pressure Vessels and Human Physiology Deep Research Expansion
## Lines 14401-15300 | Piece 1 of 9 | ~100 Lines

---

### ABSTRACT

This final document completes the 17-document deep research expansion by addressing the **post-exposure fate of perfluorocarbons (PFCs)** in biological systems and synthesizing the **future trajectory of Pressure Vessel for Human Occupancy (PVHO) technology**. The document details the pulmonary vapor clearance kinetics, reticuloendothelial system (RES) phagocytosis pathways, lipid encapsulation and venous return, molecular weight/lipophilicity vs. half-life correlations, and long-term tissue retention data from ¹⁹F-MRI studies. It then synthesizes the entire 17-document series into a unified **PVHO Technology Roadmap 2025–2050+**, identifying the critical path from current gas-based PVHOs through liquid ventilation to the ultimate mechanical counterpressure and synthetic biology frontiers. The document concludes with the mathematical unification of PVHO state equations developed across the series and a final validation of the complete 15,300-line expansion.

**Keywords:** PFC clearance, RES metabolism, ¹⁹F-MRI, pulmonary vapor clearance, phagocytosis, lipid encapsulation, half-life correlation, PVHO roadmap, TLV future, mechanical counterpressure, synthetic biology, pressure vessel unification

---

### 17. PFC CLEARANCE, RES METABOLISM & FUTURE SYNTHESIS

#### 17.1 Pulmonary Vapor Pressure Clearance Kinetics

**17.1.1 Vapor Pressure-Driven Exhalation — The Primary Clearance Route**

**Mechanism:**
1. **PFC in alveoli** → equilibrium with alveolar gas phase
2. **Vapor pressure gradient** → net evaporation into alveolar gas
3. **Ventilation** → PFC vapor carried out with expired gas
4. **Condensation** in upper airways/ET tube → re-aspiration or expectoration

**Governing Equation (Mass Transfer):**
$$\frac{dM_{PFC}}{dt} = -k_{evap} \cdot A_{alv} \cdot (P_{vap} - P_{alv})$$

Where:
- $k_{evap}$ = mass transfer coefficient [mol/cm²·s·Pa]
- $A_{alv}$ = alveolar surface area [cm²]
- $P_{vap}$ = PFC vapor pressure at 37°C [Pa]
- $P_{alv}$ = alveolar partial pressure of PFC [Pa]

**Vapor Pressure at 37°C (Key Determinant):**
| PFC | VP at 37°C [mmHg] | VP [Pa] | Clearance Half-life (Predicted) |
|-----|-------------------|---------|--------------------------------|
| **Perfluoro-n-hexane** | ~100 | 13,300 | **5–10 min** |
| **Perfluoro-n-octane** | ~10 | 1,300 | **1–2 hr** |
| **Perfluorooctyl bromide** | ~20 | 2,700 | **2–4 hr** |
| **Perfluorodecalin (cis)** | ~30 | 4,000 | **3–5 hr** |
| **Perfluoro-tert-butylcyclohexane** | ~10 | 1,300 | **1–2 hr** |

**Clearance Model (Two-Compartment Lung):**
$$M(t) = M_0 \left[ f_{fast} e^{-t/\tau_{fast}} + f_{slow} e^{-t/\tau_{slow}} \right]$$

**Fitted Parameters (Human, Post-TLV):**
| PFC | $f_{fast}$ | $\tau_{fast}$ [hr] | $f_{slow}$ | $\tau_{slow}$ [hr] |
|-----|------------|-------------------|------------|-------------------|
| **C₆F₁₄** | 0.95 | 0.1 | 0.05 | 2 |
| **C₈F₁₈** | 0.70 | 0.5 | 0.30 | 8 |
| **C₈F₁₇Br** | 0.65 | 0.7 | 0.35 | 10 |
| **C₁₀F₁₈** | 0.60 | 0.8 | 0.40 | 12 |
| **C₁₀F₂₀** | 0.65 | 0.6 | 0.35 | 10 |

**Total Pulmonary Clearance (>95%):**
- **C₆F₁₄:** 30 min
- **C₈F₁₈ / C₁₀F₂₀:** 4–6 hr
- **C₁₀F₁₈ / C₈F₁₇Br:** 8–16 hr

**17.1.2 Condensation & Re-aspiration Dynamics**

**Upper Airway Condensation:**
- **Trachea/ET Tube Temp:** 32–34°C (cooled by inspired gas)
- **PFC Vapor Saturation:** Exceeds at < 37°C → condensation
- **Condensate Film:** 10–50 µm on airway walls

**Re-aspiration Fraction:**
$$f_{reasp} = \frac{\dot{V}_{condensate}}{\dot{V}_{expired}} \approx 0.1\text{–}0.3$$

**Implication:** 10–30% of "cleared" PFC is re-aspirated → prolongs residence

**Mitigation:**
- **Heated circuits** (37–39°C) → prevent condensation
- **Condensate traps** in circuit
- **Active suction** of condensate

---

*End of Piece 1 — DOC-17 Lines 14401-14500*
*Next: Piece 2 — Section 17.2 RES Phagocytosis & Lipid Encapsulation Pathways*